Relationship of p53 and bcl-2 to Prognosis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder
1996; Lippincott Williams & Wilkins; Volume: 155; Issue: 5 Linguagem: Inglês
10.1016/s0022-5347(01)66192-5
ISSN1527-3792
AutoresSeth H. Glick, Lydia Pleotis Howell, Ralph W. deVere White,
Tópico(s)Genetic factors in colorectal cancer
ResumoNo AccessJournal of UrologyInvestigative Urology1 May 1996Relationship of p53 and bcl-2 to Prognosis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder Seth H. Glick, Lydia P. Howell, and Ralph W. Devere White Seth H. GlickSeth H. Glick More articles by this author , Lydia P. HowellLydia P. Howell More articles by this author , and Ralph W. Devere WhiteRalph W. Devere White More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66192-5AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We examined the presence of the p53 and Bcl-2 oncoproteins, as detected by immunohistochemistry, in muscle-invasive bladder cancer and correlated this with survival. Materials and Methods: Formalin-fixed cystectomy specimens from 41 consecutive patients with mean follow-up of 52 months were used. Five patients were either lost to follow-up or died of other diseases and were not included in the survival evaluation. Results: Eighteen of 36 patients died of metastatic transitional cell carcinoma. p53 immunostaining was found in 61 percent of patients. In 21 of 23 this staining was homogeneous, with more than 75 percent of cancer cells staining using a DO-1/DO-7 antibody cocktail. p53 staining was not correlated with stage (p greater than 0.25) or grade (p less than 0.10) in these invasive cancer specimens. Contrary to recent studies p53 immunostaining was not correlated with disease-specific survival. Bcl-2 immunostaining was found in 28 percent of patients and was not correlated with grade (p greater than 0.25) or disease-specific survival. No combination of p53 and Bcl-2 staining gave added predictive information. Conclusions: Cytoplasmic Bcl-2 is found in a small percentage of these cancers and does not correlate with prognosis. Further, p53 molecular overexpression is detected in the majority of muscle-invasive bladder tumors as a field defect. However, in patients undergoing cystectomy, it does not correlate with prognosis. References 1 : Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell1992; 70: 937. Google Scholar 2 : Regulation of the specific DNA binding function of p53. Cell1992; 71: 875. Google Scholar 3 : Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol1988; 8: 531. Google Scholar 4 : p53 nuclear protein accumulation correlates with mutation in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol1993; 143: 1389. Google Scholar 5 : Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst1993; 85: 53. Crossref, Medline, Google Scholar 6 : Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol1994; 152: 388. Link, Google Scholar 7 : Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med1994; 331: 1259. Google Scholar 8 : Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer1993; 53: 365. Google Scholar 9 : Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature1990; 348: 334. Google Scholar 10 : Expression in non-Hodgkin lymphoma of the bcl-2 protein associated with the t(14;18) translocation. N. Engl. J. Med1988; 318: 1638. Google Scholar 11 : Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor deprived hematopoietic cell lines. J. Immunol1990; 144: 3602. Google Scholar 12 : Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood1993; 81: 151. Google Scholar 13 : c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc. Natl. Acad. Sci. U.S.A1994; 91: 5878. Google Scholar 14 : Bcl-2 protein is topographically restricted in tissues characterized by apoptolic cell death. Proc. Natl. Acad. Sci. U.S.A1991; 88: 6961. Google Scholar 15 Daas, M., del Rosario, A. D., Bui, H. X., Singh, J. K. and Ross, J. S.: Bcl-2 protein expression is related to cellular differentiation in urinary bladder transitional cell carcinoma (UB-TCC). Presented at U.S. and Canadian Academy of Pathology, Toronto, 1995. Google Scholar 16 : Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc1958; 53: 457. Crossref, Google Scholar 17 : Quantitative flow-microfluorometric analysis of the DNA in cells from neoplasms of the urinary bladder: correlation of aneuploidy with histological grading and the cytological findings. Urol. Res1978; 6: 201. Google Scholar 18 : Identification of p53 gene mutations in bladder cancers and urine samples. Science1991; 252: 706. Crossref, Medline, Google Scholar 19 : p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer1994; 56: 347. Crossref, Medline, Google Scholar Departments of Urology and Pathology, University of California, Davis, Sacramento, California.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byO’Kane H, Watson C, Johnston S, Petak I, William R, Watson G and Williamson K (2018) Targeting Death Receptors in Bladder, Prostate and Renal CancerJournal of Urology, VOL. 175, NO. 2, (432-438), Online publication date: 1-Feb-2006.MCKNIGHT J, GRAY S, O’KANE H, JOHNSTON S and WILLIAMSON K (2018) APOPTOSIS AND CHEMOTHERAPY FOR BLADDER CANCERJournal of Urology, VOL. 173, NO. 3, (683-690), Online publication date: 1-Mar-2005.MARTINS A, FARIA S, COLOGNA A, SUAID H and TUCCI S (2018) IMMUNOEXPRESSION OF p53 PROTEIN AND PROLIFERATING CELL NUCLEAR ANTIGEN IN PENILE CARCINOMAJournal of Urology, VOL. 167, NO. 1, (89-93), Online publication date: 1-Jan-2002.TIGUERT R, BIANCO F, OSKANIAN P, LI Y, GRIGNON D, WOOD D, PONTES J and SARKAR F (2018) STRUCTURAL ALTERATION OF p53 PROTEIN IN PATIENTS WITH MUSCLE INVASIVE BLADDER TRANSITIONAL CELL CARCINOMAJournal of Urology, VOL. 166, NO. 6, (2155-2160), Online publication date: 1-Dec-2001.DUGGAN B, KELLY J, KEANE P and JOHNSTON S (2018) MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCERJournal of Urology, VOL. 165, NO. 3, (946-954), Online publication date: 1-Mar-2001.PERALTA E, LIU X, MCCARTY T, WILSON T, DIAMOND D and ELLENHORN J (2018) IMMUNOTHERAPY OF BLADDER CANCER TARGETING P53Journal of Urology, VOL. 162, NO. 5, (1806-1811), Online publication date: 1-Nov-1999.BERNARDINI S, ADESSI G, BILLEREY C, CHEZY E, CARBILLET J and BITTARD H (2018) IMMUNOHISTOCHEMICAL DETECTION OF p53 PROTEIN OVEREXPRESSION VERSUS GENE SEQUENCING IN URINARY BLADDER CARCINOMASJournal of Urology, VOL. 162, NO. 4, (1496-1501), Online publication date: 1-Oct-1999.HUANG A, FONE P, GANDOUR-EDWARDS R, DEVERE WHITE R and LOW R (2018) IMMUNOHISTOCHEMICAL ANALYSIS OF BCL-2 PROTEIN EXPRESSION IN RENAL CELL CARCINOMAJournal of Urology, VOL. 162, NO. 2, (610-613), Online publication date: 1-Aug-1999.Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y and Kawabe K (2018) COMBINED ANALYSIS WITH BCL-2 AND P53 IMMUNOSTAINING PREDICTS POORER PROGNOSIS IN PROSTATIC CARCINOMAJournal of Urology, VOL. 158, NO. 6, (2278-2283), Online publication date: 1-Dec-1997. Volume 155Issue 5May 1996Page: 1754-1757 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information Seth H. Glick More articles by this author Lydia P. Howell More articles by this author Ralph W. Devere White More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)